
Updates in management of septic shock & role of Statins in sepsis

An Essay Submitted for Partial Fulfillment of Master Degree in
Anesthesiology

By

Heba Zakaria Ahmed Yousef

M.B.B.Ch., Faculty of Medicine, Ain Shams University

Under supervision of

Professor Dr.Laila Ali El Kafrawy

Professor of anaesthesia and intensive care
Faculty of medicine, Ain Shams University

Professor Dr.Naglaa Mohamed Ali El Sayed

Professor of anaesthesia and intensive care
Faculty of medicine, Ain Shams University

Dr.Ayman Ahmed Mahmoud El Sayed

Lecturer of Anaesthesia and intensive care
Faculty of medicine, Ain Shams University

Faculty of medicine,
Ain Shams University,
Anaesthesia and intensive care department
2009

Acknowledgment

Thanks are all to GOD for blessing me this work until it reached its end. Thanks to my family for their great help and support.

I wish to express my deepest gratitude and honor to **Professor Dr. Laila Ali El Kafrawy** , Professor of anaesthesia and intensive care, Faculty of medicine, Ain Shams University, for her great help and supervision.

My special thanks and appreciation for **Professor Dr. Naglaa Mohamed Ali El Sayed**, Professor of anaesthesia and intensive care , Faculty of medicine, Ain Shams University , for her sincere efforts and her valuable guidance through out this work.

My deepest thanks are to **Dr. Ayman Ahmed Mahmoud El Sayed** ,Lecturer of Anaesthesia and intensive care, Faculty of medicine, Ain Shams University, for his generous instruction all through the work.

Heba Zakaria

Contents

- Introduction.....1
 - Definition &Diagnosis.....3
 - Pathophysiological considerations.....9
 - New treatment strategies in septic shock.....29
 - Pharmacological properties of Statins.....67
 - Role of statins in sepsis.....75
 - English summary.....83
 - References.....86
 - Arabic summary.....115
-

احداث طرق علاج الصدمه التسمميه واستخدام الستاتينز فى حالات تسمم الدم

رساله مقدمه توطنه للحصول على درجه الماجيستير فى التخذير من

الطبييه / هبه زكريا احمد يوسف

تحت اشراف

ا.د / نيلى على الكفراوى

استاذ التخذير والرعايه المركزه- كلية الطب- جامعة عين شمس

ا.د / نجلاء محمد على السيد

استاذ التخذير والرعايه المركزه- كلية الطب- جامعة عين شمس

د/ ايمن احمد محمود السيد

مدرس التخذير والرعايه المركزه- كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

قسم التخذير والرعايه المركزه

2009

List of abbreviations:

<i>ARDS</i>	Acute respiratory distress syndrome
<i>APACHE II</i>	Acute Physiology and Chronic Health Evaluation II
<i>APC</i>	Activated Protein C
<i>ALI</i>	Acute lung injury
<i>AVP</i>	Arginine vasopressin
<i>BG</i>	Blood glucose
<i>CYP</i>	Cytochrome P450 isoenzymes
<i>DIC</i>	Disseminated intravascular coagulation
<i>DO₂</i>	Oxygen delivery
<i>ECM</i>	Extracellular matrix
<i>G-CSF</i>	Granulocyte colony-stimulating factor
<i>GM-CSF</i>	Granulocyte macrophage colony-stimulating factor
<i>GTPases</i>	Guanosine triphosphatase
<i>KATP</i>	Adenosine triphosphate-sensitive potassium
<i>HDL-C%</i>	High Density Lipoproteins-Cholesterol%
<i>HMG CoA</i>	3-hydroxy-3-methylglutaryl coenzyme A
<i>ICU</i>	Intensive care unit
<i>IgG</i>	Immunoglobulin G
<i>IL-1</i>	Interleukin-1
<i>LDL-C%</i>	Low Density Lipoproteins-Cholesterol%

<i>LOS</i>	Length of stay
<i>MBP</i>	Mean blood pressure
<i>MHC</i>	Major histocompatibility complex
<i>MIF</i>	Macrophage inhibitory factor
<i>MRSA</i>	Methicillin resistant Staphylococcus aureus
<i>NAFLD</i>	Non-alcoholic fatty liver disease
<i>NASH</i>	Non-alcoholic steatohepatitis
<i>NE</i>	Norepinephrine
<i>NMBA</i>	Neuromuscular blocking agents
<i>NO</i>	Nitric oxide
<i>ORSA</i>	Oxacillin-resistant Staphylococcus aureus
<i>PAF</i>	Platelet activating factor
<i>PaO₂/FIO₂</i>	Partial arterial oxygen pressure/fraction of inspired oxygen
<i>PaCO₂</i>	Partial arterial carbon dioxide pressure
<i>PBW</i>	Predicted body weight
<i>PEEP</i>	Positive End Expiratory Pressure
<i>rhAPC</i>	Recombinant Human Activated Protein C
<i>SBP</i>	Systolic blood pressure
<i>SBT</i>	Spontaneous breathing trial
<i>ScvO₂</i>	Central venous oxygen saturation
<i>SSC</i>	Surviving Sepsis Campaign
<i>SVO₂</i>	Mixed venous oxygen saturation
<i>TFPI</i>	Tissue factor pathway inhibitor
<i>TG</i>	Triglycerides

<i>TNF</i>	Tumor necrosis factor
<i>t-PA</i>	Tissue plasminogen activator
<i>VAP</i>	Ventilator-associated pneumonia
<i>WBC</i>	White blood cells count

List of figures :

Figure (1)	<i>Proposed mechanism of action of activated protein C .</i>
Figure (2)	<i>Coagulation, anticoagulant mechanisms, and fibrinolysis in sepsis.</i>
Figure(3)	<i>Coagulation imbalance during sepsis.</i>
Figure (4)	<i>Apoptosis and caspases regulate death and inflammation in sepsis</i>
Figure (5)	<i>The statin pharmacophore.</i>
Figure (6)	<i>Lovastatin, a type 1 statin .</i>
Figure (7)	<i>Fluvastatin, a type 2 statin</i>
Figure (8)	<i>Molecular mechanism of action of statins.</i>

List of tables:

<i>Table (1)</i>	<i>Mediators of Sepsis</i>
<i>Table(2)</i>	<i>The Leuven Algorithm</i>
<i>Table (3)</i>	<i>Comparative efficiency and pharmacology of the statins</i>

INTRODUCTION

Sepsis reflects the delicate balance between defense mechanisms against invading micro-organisms and both direct and indirect effects of these micro-organisms and their products. Severe sepsis is accompanied by the inability to regulate the inflammatory response. The cause of that is unknown (*Riedemann et al, 2003*). Except in few occasions, patients appear to die from the body's response to infection rather than from infection itself (*Novack et al, 2006*).

Numerous trials have failed to demonstrate that blocking specific inflammatory mediators is beneficial in sepsis. Despite this frustration, new strategies are being explored (*Riedemann et al, 2003*). However, in complex situations such as severe sepsis, multiple cellular activation processes are involved, so blocking a single component may be insufficient to arrest the inflammatory process (*Almog, 2003*).

Severe sepsis and septic shock are major healthcare problems, affecting millions of individuals around the world each year, killing one in four and often more, and increasing in incidence. The speed and appropriateness of therapy administered in the initial hours after severe sepsis influence outcome (*Linde-Zwirble & Angus, 2004*).

Statins have a variety of properties that are independent of their lipid lowering ability. These anti-inflammatory,

antioxidant, immunomodulatory, and antiapoptotic properties have been collectively referred to as pleiotropic effects (*Blanco-Colio et al, 2003*).

Definition & Diagnosis

Severe sepsis is an infection-induced inflammatory syndrome that ultimately leads to organ dysfunction. It is estimated that more than 500,000 episodes of sepsis occur each year in the USA alone, and that 20–50% of these patients will die (*Martin et al, 2003*). The incidence of sepsis and number of sepsis-related deaths appear to be increasing. Important progress has been made in recent years, and interventions such as activated protein C, early goal-directed therapy, and possibly low-dose corticosteroids have been shown to improve survival in patients with severe sepsis (*Riedemann et al, 2003*). Despite these advances, mortality remains unacceptably high and care for patients with sepsis costs as much as \$50,000 per patient, resulting in an economic burden of nearly \$17 billion annually in the USA alone (*Martin et al, 2003*).

Sepsis is defined as infection plus systemic manifestations of infection (Scheme 1). Sepsis is an inflammatory injury to the body resulting from the host immune response to an infectious stimulus. Uncomplicated sepsis, such as that caused by 'flu and other viral infections, gastroenteritis, or dental abscesses, is very common and is experienced by millions of people each year. Death is common among sepsis patients, with around 28–50%. The majority of these people will not need hospital treatment (*Levy et al, 2003*).

Severe sepsis is defined as sepsis plus sepsis-induced organ dysfunction or tissue hypoperfusion. Threshold for this dysfunction has varied somewhat from one severe sepsis research study to another. An example of typical thresholds identification of severe sepsis is shown in Scheme (2). Sepsis induced hypotension is defined as a systolic blood pressure (SBP) <90 mm Hg or mean arterial pressure <70 mm Hg or a SBP decrease >40 mm Hg in the absence of other causes of hypotension. Severe sepsis is a complex and often life-threatening condition. It can affect anyone but often develops in patients with pneumonia, trauma, surgery, burns or cancer. Severe sepsis results in the hospitalization of more than 750,000 people each year in the United States and similar in Europe. These patients have a mortality rate of approximately 30-35 % (*Levy et al, 2003*).

Septic shock is defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation. Sepsis induced tissue hypoperfusion is defined as septic shock, an elevated lactate or oliguria (*Sepsis Definitions Conference, 2003*). Septic shock refers to sepsis patients with arterial hypotension that is refractory to adequate fluid resuscitation and leads to problems in one or more of the vital organs, the body does not receive enough oxygen to properly function, thus requiring vasopressor administration. Septic shock patients are very ill and need rapid emergency admission to the hospital intensive care unit ("ICU"). Despite active treatment in the ICU, the death rate is around 50%. Sepsis has risen to the 10th leading cause of death in United States (*Levy et al, 2003*).

Diagnosis can be difficult as some of the symptoms of sepsis, such as fever, rapid pulse and respiratory difficulty, are very general and can be found in many other disorders. The symptoms of sepsis can easily be attributed to other conditions, creating problems of late or misdiagnosis

Scheme (1): (*Levy et al, 2001*)

Diagnostic criteria for sepsis

1-General variables

- Fever ($>38.3^{\circ}\text{C}$)
- Hypothermia (core temperature $<36^{\circ}\text{C}$)
- Heart rate >90 min or >2 SD(Standard Deviation) above the normal value for age
- Tachypnea
- Altered mental status
- Significant edema or positive fluid balance (>20 mL/kg over 24 hrs)
- Hyperglycemia (plasma glucose >140 mg/dL or 7.7 mmol/L) in the absence of diabetes

2-Inflammatory variables

- Leukocytosis (WBC count $>12,000/\mu\text{L}$ -1)
- Leukopenia (WBC count $<4000 /\mu\text{L}$ -1)
- Normal WBC count with $>10\%$ immature forms
- Plasma C-reactive protein >2 SD above the normal value
- Plasma procalcitonin >2 SD above the normal value

3-Hemodynamic variables

Arterial hypotension (SBP <90 mm Hg; MAP <70 mm Hg; or an SBP decrease >40 mm Hg in adults or >2 SD below normal for age)

4-Organ dysfunction variables

- Arterial hypoxemia (PaO₂/FIO₂ <300)
- Acute oliguria (urine output <0.5 mL/Kg/ hr or 45 mmol/L for at least 2 hrs, despite adequate fluid resuscitation)
- Creatinine increase >0.5 mg/dL or 44.2 μmol/L
- Coagulation abnormalities (INR >1.5 or a PTT >60 secs)
- Ileus (absent bowel sounds)
- Thrombocytopenia (platelet count <100,000 μL⁻¹)
- Hyperbilirubinemia (plasma total bilirubin >4 mg/dL)

5-Tissue perfusion variables

- Hyperlactatemia
- Decreased capillary refill or mottling

Diagnostic criteria for sepsis in the pediatric population are signs and symptoms of inflammation

Plus infection with hyper- or hypothermia (rectal temperature >38.5°C or <35°C), tachycardia (may be absent in hypothermic patients), and at least one of the following